<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sharma M</submitter><funding>National Institute of Pharmaceutical Education and Research, Ahmedabad</funding><funding>Department of Chemicals and Petrochemicals, Ministry of Chemicals and Fertilizers</funding><funding>European Commission</funding><funding>Department of Biotechnology, Ministry of Science and Technology, India</funding><pagination>40-51</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9841796</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(1)</volume><pubmed_abstract>Parkinson's disease (PD) is a progressive neurodegenerative disease with no permanent cure affecting around 1% of the population over 65. There is an urgency to search for a disease-modifying agent with fewer untoward effects. PD pathology involves the accumulation of toxic alpha-synuclein (α-syn) and neuronal inflammation leading to the degeneration of dopaminergic (DAergic) neurons. Swertiamarin (SWE), a well-studied natural product, possesses a strong anti-inflammatory effect. It is a secoiridoid glycoside isolated from &lt;i>Enicostemma littorale&lt;/i> Blume. SWE showed a reversal effect on the α-syn accumulation in the 6-hydroxydopamine (6-OHDA)-induced &lt;i>Caenorhabditis elegans&lt;/i> model of PD. However, there are no reports in the literature citing the effect of SWE as a neuroprotective a</pubmed_abstract><journal>ACS pharmacology &amp; translational science</journal><pubmed_title>Neuroprotective Effect of Swertiamarin in a Rotenone Model of Parkinson's Disease: Role of Neuroinflammation and Alpha-Synuclein Accumulation.</pubmed_title><pmcid>PMC9841796</pmcid><funding_grant_id>LX22NPO5107</funding_grant_id><pubmed_authors>Sharma N</pubmed_authors><pubmed_authors>Kate AS</pubmed_authors><pubmed_authors>Juvvalapalli SS</pubmed_authors><pubmed_authors>Goswami A</pubmed_authors><pubmed_authors>Khairnar A</pubmed_authors><pubmed_authors>Malim FM</pubmed_authors><pubmed_authors>Chatterjee S</pubmed_authors><pubmed_authors>Sharma M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Neuroprotective Effect of Swertiamarin in a Rotenone Model of Parkinson's Disease: Role of Neuroinflammation and Alpha-Synuclein Accumulation.</name><description>Parkinson's disease (PD) is a progressive neurodegenerative disease with no permanent cure affecting around 1% of the population over 65. There is an urgency to search for a disease-modifying agent with fewer untoward effects. PD pathology involves the accumulation of toxic alpha-synuclein (α-syn) and neuronal inflammation leading to the degeneration of dopaminergic (DAergic) neurons. Swertiamarin (SWE), a well-studied natural product, possesses a strong anti-inflammatory effect. It is a secoiridoid glycoside isolated from &lt;i>Enicostemma littorale&lt;/i> Blume. SWE showed a reversal effect on the α-syn accumulation in the 6-hydroxydopamine (6-OHDA)-induced &lt;i>Caenorhabditis elegans&lt;/i> model of PD. However, there are no reports in the literature citing the effect of SWE as a neuroprotective a</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-05T16:14:08.838Z</modification><creation>2025-04-05T16:14:08.838Z</creation></dates><accession>S-EPMC9841796</accession><cross_references><pubmed>36654754</pubmed><doi>10.1021/acsptsci.2c00120</doi></cross_references></HashMap>